Credit: Canva
People with blood cancers often receive blood or bone marrow transplants. However, even with these treatments, the risk of relapse is high. A clinical trial led by Christopher G. Kanakry, M.D., Lasker Clinical Research Scholar in the Center for Immuno-Oncology, is researching bone marrow transplants containing lymphocytes, a type of white blood cell, and whether they can help reduce relapse risk. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Ashley DeVries at (240) 858-7529 or ashley.devries@nih.gov
Clinicaltrials.gov identifier: NCT05327023
NCI Protocol ID: 000359
Official Title: Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.